Journal of metabolic and bariatric surgery最新文献

{"title":"Clinical Outcomes of Alternate Laparoscopic Linear Stapler in Primary Sleeve Gastrectomy: A Single-Center Retrospective Study of Safety and Feasibility.","authors":"Sol Lee, Sang-Moon Han","doi":"10.17476/jmbs.2026.15.1.44","DOIUrl":"10.17476/jmbs.2026.15.1.44","url":null,"abstract":"<p><strong>Purpose: </strong>Staple line bleeding and leak are recognized sources of morbidity in sleeve gastrectomy, with reported rates of 1-5% and 1-3%, respectively. This study evaluated the safety and feasibility of an alternate laparoscopic linear stapling device in primary sleeve gastrectomy.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed 100 consecutive patients who underwent primary laparoscopic sleeve gastrectomy using an alternate laparoscopic linear stapler (iREACH OMNIA; Reach Surgical, Inc.) between January 2024 and February 2025 at Seoul Medical Center. Patients were stratified by body mass index (BMI) class: Class I (30-34.9 kg/m²; n=42), Class II (35-39.9 kg/m²; n=40), and Class III (≥40 kg/m²; n=18). Primary outcomes were staple line bleeding, leak, and reoperation rates. Secondary outcomes included estimated blood loss, length of hospital stay, 30-day complications, and 1-month weight loss.</p><p><strong>Results: </strong>No staple line complications were observed: staple line bleeding 0% (95% confidence interval [CI], 0-3.7%), leak 0% (95% CI, 0-3.7%), and reoperation 0%. Estimated blood loss was 98.3±42.5 mL (P=0.362) and length of stay 5.1±0.5 days (P=0.758), both uniform across BMI groups. A standardized stapler configuration (1 Black + 4-5 Purple cartridges) was used in over 90% of cases regardless of BMI class. At 1-month follow-up, % total weight loss by group was 11.75±3.35%, 13.42±6.37%, and 13.79±4.27% for Classes I, II, and III, respectively, and % excess weight loss was 49.93%, 41.43%, and 33.41%.</p><p><strong>Conclusion: </strong>The alternate laparoscopic linear stapler demonstrated a favorable safety profile in primary sleeve gastrectomy, with no observed staple line complications across BMI categories. Larger multicenter comparative studies with longer follow-up are warranted to confirm these findings.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"15 1","pages":"44-51"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147935904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Procedure: Revisiting the Technical Determinants of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass.","authors":"Dongjae Jeon, Mira Yoo, So Hyun Kang, Tae-Han Kim, Yun-Suhk Suh, Young Suk Park","doi":"10.17476/jmbs.2026.15.1.20","DOIUrl":"10.17476/jmbs.2026.15.1.20","url":null,"abstract":"<p><p>Metabolic and bariatric surgery has become an increasingly technique-sensitive field in which even modest intraoperative variations may influence postoperative physiology and long-term outcomes. Although sleeve gastrectomy and Roux-en-Y gastric bypass are well-established procedures, substantial heterogeneity persists in how key technical steps are performed. This review revisits several high-impact technical determinants that remain clinically relevant in routine practice, focusing on antral preservation and bougie calibration in sleeve gastrectomy, and pouch size and gastrojejunostomy (GJ) stoma diameter in Roux-en-Y gastric bypass. In sleeve gastrectomy, more aggressive antral resection and smaller bougie calibers may confer a modest short-term weight-loss advantage, but these benefits appear to be offset by trade-offs involving reflux, stricture, and postoperative intolerance. In Roux-en-Y gastric bypass, smaller gastric pouches and avoidance of an excessively wide GJ are generally associated with more favorable weight-loss outcomes, although reproducibility of construction may be more important than any single numeric target. Overall, current evidence does not support one universally ideal technical configuration. Rather, it supports a balanced strategy based on standardized, reproducible baseline technique, avoidance of extremes, and selective personalization according to patient phenotype, risk profile, and treatment goals.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"15 1","pages":"20-27"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147935941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 Receptor Agonist Combination Therapy Before and After Metabolic and Bariatric Surgery: A Review of Outcomes.","authors":"Chang Seok Ko","doi":"10.17476/jmbs.2026.15.1.28","DOIUrl":"10.17476/jmbs.2026.15.1.28","url":null,"abstract":"<p><p>The paradigm of obesity treatment is rapidly evolving with the introduction and widespread adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Semaglutide, the representative agent, has demonstrated substantial weight reduction and cardiometabolic benefits across multiple pivotal clinical trials, reshaping societal perceptions of anti-obesity pharmacotherapy. In parallel, sleeve gastrectomy (SG) has become the most commonly performed metabolic and bariatric surgical procedure worldwide due to its technical simplicity, strong safety profile, and durable outcomes. The use of anti-obesity medication in the preoperative setting of metabolic and bariatric surgery has been previously explored; however, its clinical benefit has long remained controversial and inconsistent. Recent evidence suggests that GLP-1 RAs can safely achieve greater preoperative weight loss than earlier pharmacologic agents. Furthermore, GLP-1 RAs have emerged as an effective treatment option for postoperative weight regain, demonstrating significant weight-loss benefits in both SG and gastric bypass patients compared with conventional therapies. As GLP-1-based therapies continue to advance, future strategies should shift toward a multimodal treatment model analogous to oncology, integrating pharmacologic and surgical interventions throughout all phases of obesity care. Further research is needed to establish the ideal timing, duration, safety, and long-term weight loss and metabolic effects of GLP-1 RA administration in both pre- and postoperative phases.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"15 1","pages":"28-36"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147935947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleeve Gastrectomy With Proximal Jejunal Bypass: Balancing Simplicity and Efficacy in Metabolic and Bariatric Surgery.","authors":"Sang-Yong Son, Yeo-Jin Boo, Jeong Ho Song, Hoon Hur, Sang-Uk Han","doi":"10.17476/jmbs.2026.15.1.1","DOIUrl":"10.17476/jmbs.2026.15.1.1","url":null,"abstract":"<p><p>Sleeve gastrectomy with proximal jejunal bypass (SG-PJB) is a simplified sleeve-plus procedure designed to augment the metabolic impact of sleeve gastrectomy while avoiding the long-term complications associated with Roux-en-Y gastric bypass (RYGB). Early studies demonstrate that SG-PJB achieves diabetes remission and metabolic improvements comparable to RYGB, with sustained insulin independence in previously insulin-dependent patients. The procedure preserves duodenal continuity and maintains physiologic nutrient absorption, and no cases of hypoalbuminemia or bacterial overgrowth have been reported. Despite its promising balance of metabolic efficacy and nutritional safety, further research is required to clarify optimal indications, determine appropriate bypass limb lengths, and validate long-term safety. As current data suggest, SG-PJB offers a favorable risk-benefit profile and may become a valuable alternative within the sleeve-plus spectrum.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"15 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147935888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One Anastomosis Gastric Bypass in Patients With a BMI ≥50 kg/m²: A Systematic Review and Single-Arm Meta-Analysis of Outcomes.","authors":"Mostafa Mohammed Saad Mahran, Neha Patel, Karim Ataya, Dima Salloum, Almoutuz Aljaafreh, Devalia Kalpana, Adam Goralczyk, Kozar Agha, Oday Al Asadi, Wah Yang","doi":"10.17476/jmbs.2025.14.3.174","DOIUrl":"10.17476/jmbs.2025.14.3.174","url":null,"abstract":"<p><strong>Purpose: </strong>The prevalence of individuals with obesity classes 4 and 5 is increasing, with no optimal surgical approach identified. With the rising popularity of one anastomosis gastric bypass (OAGB), we conducted a single-arm meta-analysis to assess its outcomes in this population.</p><p><strong>Materials and methods: </strong>A comprehensive search of PubMed, Scopus, EMBASE, and Cochrane identified studies on OAGB reporting weight loss, comorbidity remission, and complications. Statistical analysis was performed using RStudio 4.4.1. Heterogeneity was assessed using the Cochrane Q test and I² statistics.</p><p><strong>Results: </strong>Seventeen studies including 2,274 patients (mean age, 40.44 years), were identified. The analysis revealed a rising trend up to 24 months, with a pooled excess weight loss (%) of 68.08% (95% confidence interval [CI], 63.64-72.52; I²=95.6%), and total weight loss (%) of 36.63% (95% CI, 35.34-37.92; I²=84.6%) at 12 months. Diabetes and hypertension remission rates were 82.02% (95% CI, 70.36-89.77; I²=59.5%) and 78.06% (95% CI, 59.05-89.77; I²=84.9%), respectively. The incidence of de novo gastroesophageal reflux disease was 4.38% (95% CI, 0.61-25.59; I²=91.9%).</p><p><strong>Conclusion: </strong>OAGB can be a valuable option for this population, awaiting long-term data.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"14 3","pages":"174-192"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146020728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication Adjustment After Bariatric and Metabolic Surgery: A Review of Current Evidence and Clinical Practice Trends.","authors":"Ji-Hyeon Park, Sojung Kim, Ho Seok Seo, Kyo Young Song, Han Hong Lee","doi":"10.17476/jmbs.2025.14.3.193","DOIUrl":"10.17476/jmbs.2025.14.3.193","url":null,"abstract":"<p><p>Bariatric and metabolic surgery (BMS) is the most effective treatment for severe obesity and its related comorbidities. Rapid metabolic improvement following surgery frequently leads to the reduction or discontinuation of medications for obesity-related comorbidities. However, there are no established guidelines regarding timing or criteria for dose adjustment. A narrative review examined major clinical trials, meta-analyses, and society guidelines relevant to BMS. Evidence from previous and recent studies was synthesized to summarize pharmacokinetic alterations, disease-specific medication adjustments, and long-term deprescription patterns following BMS. Postoperative anatomical changes-including reduced gastric surface area, intestinal bypass, and altered acidity-affect the absorption of many oral drugs, requiring early dose adjustment. For type 2 diabetes mellitus, patients using <30 units/day of basal insulin can discontinue insulin after surgery, whereas those using ≥30 units/day typically require a 50-80% dose reduction. Most patients taking a single oral hypoglycemic agent may stop medication, while metformin monotherapy is recommended when glycated hemoglobin (HbA1c) <9% and dual therapy when HbA1c ≥9%. In hypertension, discontinuation of one antihypertensive drug usually results in approximate 10 mmHg reduction in systolic blood pressure. Diuretics should be withheld for the first 2 weeks postoperatively to prevent dehydration and excessive volume loss. For dyslipidemia, lipid-lowering agents are adjusted according to postoperative lipid profile changes and restarted if necessary. In psychiatric disorders, early resumption of preoperative medications is recommended to prevent withdrawal symptoms or relapse. BMS enables early medication reduction across comorbidities, yet individualized pharmacologic management remains essential to sustain metabolic improvement and long-term disease control.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"14 3","pages":"193-201"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146020777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic and Bariatric Surgery for Class I Obesity (Body Mass Index 30-34.9 kg/m²): A Comprehensive Literature Review.","authors":"Inyoung Lee, Jeongwoo Kim, Ahmed Alkhaldi, Sultan Sulaiman A Alayed, Eman Mohammed Fallata, Mohannad Eledreesi, Osama Abdulwahed Bakkari, Abdulaziz A AlMulhem, Yeongkeun Kwon, Jae-Seok Min, Sungsoo Park","doi":"10.17476/jmbs.2025.14.3.165","DOIUrl":"10.17476/jmbs.2025.14.3.165","url":null,"abstract":"<p><p>Class I obesity (body mass index [BMI]: 30-34.9 kg/m²) constitutes a considerable portion of the global obesity burden; however, traditional guidelines for metabolic bariatric surgery (MBS) have historically excluded this population. Recent updates in clinical consensus have expanded surgical eligibility, particularly for patients with obesity-related comorbidities refractory to medical treatment. To synthesize evidence from clinical studies, international guidelines, and expert consensus to assess the efficacy, safety, and long-term outcomes of MBS in patients with class I obesity. A comprehensive literature review was conducted, incorporating major clinical trials, observational cohorts, and meta-analyses published between 2006 and 2024. Weight loss, metabolic outcomes, and major surgical complication rates were examined. Recent studies demonstrate that MBS in patients with class I obesity achieves a total weight loss of 15.8-33.7%, and excess weight loss up to 102.7%, with type 2 diabetes mellitus remission rates frequently exceeding 60%. Complication rates remain low and are comparable to those observed in cohorts with higher BMI. Indirect comparisons suggest that the metabolic benefits and safety profiles in class I obesity are comparable to those in patients with higher BMI. Updated guidelines from international bariatric societies support MBS in class I obesity. MBS is an effective and safe treatment for weight loss and remission of comorbidities in class I obesity. Supported by recent guidelines and expert consensus, it should be considered as a valid treatment option for appropriately selected patients, with the potential to reduce their long-term healthcare burden.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"14 3","pages":"165-173"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146020764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Bariatric Surgery at Risk Due to Semaglutide?","authors":"Jane Tian, Shubham Bhatia, Christina Sneed, Patrick Kiarie, Mikayla Fuchs, Andrew Miele, Darshak Shah, Noman Khan, Martine A Louis","doi":"10.17476/jmbs.2025.14.3.202","DOIUrl":"10.17476/jmbs.2025.14.3.202","url":null,"abstract":"<p><strong>Purpose: </strong>Obesity remains a significant public health issue in the Western world, affecting millions of Americans and contributing to chronic conditions such as diabetes and hypertension. In June 2021, the Food and Drug Administration approved semaglutide for long-term weight management. While its effectiveness in promoting weight loss has been well-documented, its impact on the field of bariatric surgery remains uncertain.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on 515 bariatric patients from January 2022 to November 2023. Patients on semaglutide in the preoperative period were compared to those not using the medication, with outcomes including time to surgery, cancellation rates, weight loss at different time points, and secondary outcomes such as side effects.</p><p><strong>Results: </strong>Thirteen percent of patients were on semaglutide. Semaglutide users had higher rates of diabetes (P<0.001). Starting and preoperative weights were comparable between both groups. Patients on semaglutide were less likely to proceed with surgery (P=0.001). For patients who had surgery, those on semaglutide experienced longer times from evaluation to surgery, compared to patients not taking this medication (8.8 months vs. 7.4 months, P=0.152). Weight loss outcomes at 2- and 6-month post-surgery were similar between groups. Notably, 22% of semaglutide patients no longer qualified for surgery due to successful weight loss.</p><p><strong>Conclusion: </strong>The use of semaglutide has the potential to reduce the number of bariatric surgeries and delay surgical intervention for some patients. However, the long-term effects of semaglutide on weight maintenance and its broader implications for clinical practice require further investigation.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"14 3","pages":"202-209"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146020736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous Transversus Abdominis Plane Block After Laparoscopic Sleeve Gastrectomy in 50 Consecutive Cases.","authors":"Yoona Chung, Yong Jin Kim, Suyeon Park","doi":"10.17476/jmbs.2025.14.3.220","DOIUrl":"10.17476/jmbs.2025.14.3.220","url":null,"abstract":"<p><strong>Purpose: </strong>Enhanced recovery after bariatric surgery is important for decreasing morbidity, enhancing functional recovery and shortening the length of stay. Ultrasound-guided transversus abdominis plane (TAP) block has been known to decrease pain scores and opioid requirement after bariatric surgery. We aimed to investigate the efficacy of continuous TAP block in 50 consecutive cases of laparoscopic sleeve gastrectomy (LSG).</p><p><strong>Materials and methods: </strong>From February 2022 to April 2022, 50 cases of LSG were performed with ultrasound-guided TAP blocks. The data was compared to that of 157 cases of primary LSG that had been performed from January to December of 2021. Ultrasound guided TAP block was performed from the epigastric port site 3 to 5 mm in size that was placed for liver retraction during LSG. The lateral border of the rectus abdominis muscle was identified. A 17-gauge T-peel inducer and sheath (On-Q^® Pain Buster^®) were inserted in a medial to lateral direction towards the TAP. Fifteen to 20 mL of normal saline was injected for plane dissection and the catheter was inserted through the sheath after removal of the inducer. The same was performed for the other side in the same order. The elastomeric pump was injected with 100 mg of 0.5% bupivacaine and connected to the 2 catheters.</p><p><strong>Results: </strong>There was no significant difference in mean age, initial body weight, preoperative body mass index (BMI), incidence of diabetes, hypertension, obstructive sleep apnea, and length of postoperative hospital stay between the TAP group and the non-TAP group. The TAP group had a higher incidence of dyslipidemia. There were statistically significant differences in the clinical outcomes regarding the numerical rating scale (NRS) score at postoperative 12, 24 and 48 hours, opioid injection within 24 hours (non-TAP group 36.82% vs. TAP group 20%, P value=0.037) and ramosetron injection within 24 hours (non-TAP group 9.45% vs. TAP group 0%, P value=0.017). There was no significant difference between the 2 groups in postoperative NRS scores at 1 and 6 hours, incidence of nausea or vomiting, injection of acetaminophen, non-steroidal anti-inflammatory drugs, or metoclopramide within 24 or 48 hours, injection of opioid or ramosetron within 48 hours. There were 2 cases of complications related to continuous TAP block where there was difficulty in removing the catheters and needed to be removed under local anesthesia.</p><p><strong>Conclusion: </strong>Although continuous TAP block did not reduce cumulative opioid consumption, the need for additional opioid and antiemetic injection can be reduced within the postoperative 24 hours.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"14 3","pages":"220-230"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146020783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Anaemia and Related Micronutrient Deficiencies After Bariatric Surgery.","authors":"Wei Wei Ng, Ijaz Binti Hallaj Rahmatullah, Norasyikin Binti A Wahab, Chee Xian Tan, Anilah Binti Abdul Rahim","doi":"10.17476/jmbs.2025.14.3.210","DOIUrl":"10.17476/jmbs.2025.14.3.210","url":null,"abstract":"<p><strong>Purpose: </strong>Anaemia and micronutrient deficiencies are common complications following bariatric surgery. This study aimed to determine the prevalence of anaemia after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), and to identify anaemia associated risk factors.</p><p><strong>Materials and methods: </strong>A cross-sectional study was conducted among 100 adults who underwent RYGB or SG between 2016 and 2022 at Hospital Raja Permaisuri Bainun, Ipoh. Demographics, biochemical parameters, and multivitamin (MVT) adherence data were analysed according to the type of surgery.</p><p><strong>Results: </strong>Among the participants, 44 underwent RYGB and 56 underwent SG, with a mean follow-up of 3 years. Most were female and over half were still menstruating. The overall prevalence of anaemia increased from 14% pre-surgery to 47% post-surgery. Anaemia increased from 9.1% to 47.7% in the RYGB group and from 17.9% to 46.4% in the SG group, with no significant difference in severity of anaemia (P=0.897). Postoperatively iron, folate and vitamin B12 deficiencies were observed in 44%, 14%, and 9% of patients, respectively. Folate deficiency was higher after SG (23.2% vs. 2.3%, P=0.003), while vitamin B12 deficiency occurred only after RYGB (20.5% vs. 0%, P<0.001). Iron deficiency was slightly higher in the RYGB group but not statistically significant (P=0.547). Menstruating females had higher risk of iron deficiency (P=0.001). Only 46% showed good adherence to MVT intake.</p><p><strong>Conclusion: </strong>Anaemia affected nearly half of post-bariatric surgery patients, with menstruating women at highest risk. Lifelong monitoring and prophylactic iron supplementation are essential to prevent anaemia and related micronutrient deficiencies.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"14 3","pages":"210-219"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146020797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}